Hansoh Pharma's Hepatitis B Drug Hengmu (Tenofovir Amibufenamide) Recommended in National Guideline for Prevention of HBV Reactivation in High-Risk Populations

Recently, the "Guidelines for the Prevention and Treatment of Hepatitis B Virus Reactivation in High-Risk Populations in China (" was jointly formulated by the National Center for Infectious Diseases Medicine, the Infectious Diseases Branch of the Chinese Medical Association, and the Editorial Board of the Chinese Journal of Infectious Diseases.2026Year Edition)" (hereinafter referred to as: "Guidelines") was officially released, providing guidance for high-risk groups in China regarding the Hepatitis B virus (HBV)The management of reactivation provides systematic and authoritative evidence-based practice guidance. Hansoh Pharma's independently developed first original oral anti-hepatitis B virus drug in China - Aimitinovir (Hengmu,TMF) As a new generation of nucleoside (acid) classHBVAntiviral drugs are explicitly listed as preventive measures in the "Guidelines."HBVOne of the recommended drugs for reactivation.

HBVReactivation is an important issue in clinical practice, especially in patients receiving immunosuppressive therapy, immune checkpoint inhibitors, chimeric antigen receptorTCell Therapy (CAR-T) and other high-risk populations such as organ transplant recipients, it may lead to hepatitis activity or even liver failure, endangering life. Therefore, scientific and standardized drug prevention is crucial. Based on the latest domestic and international evidence, and combined with clinical practice in China, the Guidelines systematically organize and recommend preventive strategies under different immunosuppressive regimens, offering significant clinical guidance value.

Among them, regarding the clinical question of "Which antiviral drug should be chosen to prevent the reactivation of the hepatitis B virus?" the Guidelines recommend selecting drugs with a high genetic barrier to resistance for prophylactic anti-hepatitis B virus treatment. Several nucleos(t)ide analogs are listed, including Tenofovir Alafenamide, with a strong recommendation and high-quality evidence.

Since its launch, Hengmu, with its potent virus suppression, high resistance barrier, and good safety profile, has been widely used in the treatment of chronic hepatitis B. This inclusion in the national prevention and treatment guidelines marks its role in prevention.HBVThe clinical value in the field of reactivation has gained authoritative recognition, offering a more reliable treatment option for a wide range of high-risk patients.

Hansoh Pharma is a leading innovation-driven pharmaceutical company in China, with subsidiaries including Hansoh Pharmaceuticals, Changzhou Hengbang Pharmaceuticals, and Hansoh Biologics. The company focuses on major disease treatment areas such as oncology, anti-infectives, central nervous system, metabolism, and autoimmune diseases. To date, the innovative drugs that have generated sales revenue in China are...7, with a rich product pipeline.